**Ticker: SAMSRITA | Sector: Health Care / Diversified Deep-Tech** Samsrita Labs Limited (formerly **Dr Habeebullah Life Sciences Ltd**) is an Indian listed entity currently undergoing a radical strategic transformation. Historically focused on hospital services and stem cell research, the company is pivoting toward a high-growth, multi-sectoral model encompassing **Bio-Pharma R&D**, **Deep Technologies**, **Green Energy**, and **Pet Healthcare**. The company utilizes a bilateral business strategy designed to balance long-term innovation with immediate revenue generation. --- ### Strategic Pivot: The Bilateral Business Model The company has restructured its operations to mitigate the inherent risks of the pharmaceutical sector while pursuing high-alpha growth opportunities: * **High-Value Creation Track:** Focused on **New Drug Discovery (NDD)**, the manufacturing of **Specialty Generics**, and the development of **Active Pharmaceutical Ingredients (APIs)**. This track targets high profit margins through intellectual property (IP) and proprietary research. * **Revenue Generation Track:** Designed to provide immediate cash flow and operational stability through the **trading, distribution, and import/export of drugs**, alongside established healthcare and diagnostic services. * **Inorganic Growth Engine:** Management is aggressively seeking to acquire controlling interests in established businesses within the **Deep Tech** and **Green Tech** domains to accelerate the transition from a service provider to a technology-led conglomerate. --- ### Core Operational Segments & Market Expansion While the Board of Directors (acting as the **Chief Operating Decision Maker**) identifies **Healthcare Services** as the primary reportable segment under **Ind AS 108**, the company has significantly broadened its **Memorandum of Association (MoA)** to enter the following high-growth markets: #### 1. Bio-Pharma & Oncology R&D The company is transitioning from clinical services to high-end pharmaceutical research. * **Key IP Acquisition:** In **October 2025**, the company purchased a patent for **"Drug Conjugated Ultra-Small Gold Nanoparticle for Effective Killing of Drug-Resistant Cancer Cells"** for **Rs. 2 Crores**. * **Asset Monetization:** Through its associate, **Krisani Bio Sciences**, the company has access to **12 international granted patents**, which it intends to commercialize via out-licensing or direct sales. #### 2. Green Technologies & Sustainability Targeting an Indian sustainability market projected to reach **US$8,603.2 Million by 2033** (**27.36% CAGR**): * **Waste Management:** Addressing a sector valued at **US$32.81 Billion (2024)** through advanced recycling and environmental solutions. * **Renewable Energy:** Exploring ventures in **Biofuels**, **EV Technology**, and sustainable materials. #### 3. Deep Technologies Integrating **AI, Blockchain, IoT, and Cloud Computing** into industrial and healthcare solutions to drive digital transformation. #### 4. Pet Animal Healthcare & Wellness Launched in **March 2026**, this division targets a market with a **CAGR of >20%**. The strategy leverages the "Pet Humanization" trend, converting traditional grooming services into essential medical wellness categories. --- ### Corporate Structure & Strategic Investments Samsrita Labs operates as a standalone entity but extends its market reach through significant stakes in associate companies: | Entity | Stake | Strategic Value | | :--- | :--- | :--- | | **Qrops Advisory Services Pvt Ltd** | **28.62%** | Provides a gateway to the **MSME** funding landscape and connections with **HNIs, VC, and PE funds**. | | **Krisani Bio Sciences Pvt Ltd** | **32.91%** | Holds a portfolio of **12 international patents**; currently subject to legal proceedings. | *Note: The company currently has **no subsidiaries or joint ventures**.* --- ### Financial Position & Capital Structure The company is currently in a "cleanup and recapitalization" phase, streamlining its balance sheet to support new ventures. **Key Financial Metrics (As of March 31, 2025):** * **Authorized Share Capital:** Increased to **Rs. 25 Crores** (from **Rs. 16 Crores**) in May 2025. * **Paid-up Capital:** **Rs. 14.81 Crores** (1,48,08,706 shares). * **Gearing Ratio:** **16.39%** (reflecting a low-debt, equity-heavy capital structure). * **Return on Net Worth:** **-1.75%** (reflecting the pre-revenue stage of new ventures). * **Dematerialization:** **98.53%** of equity is held electronically (**64.39% NSDL**, **34.15% CDSL**). **Recent Financial Adjustments:** * **Asset Write-offs:** In Q3 FY26, the company wrote off **Rs. 3.26 Crores** in intangible assets (patents) due to **technological obsolescence**. * **Provisioning:** Created a provision of **Rs. 2.09 Crores** for doubtful trade receivables and wrote off **Rs. 2.59 Crores** in long-pending advances to clean the balance sheet. * **Non-Cash Acquisitions:** Acquired a patent valued at **Rs. 2.36 Crores** via a set-off of earlier deposits. --- ### Governance & Leadership The leadership team has been refreshed to align with the new focus on digital and sustainable technologies: * **Executive Chairman & WTD:** **Mr. K. Krishnam Raju** (Re-appointed until **Dec 2024**). * **WTD & CFO:** **Mr. K.N.V. Narendra Kumar** (Re-appointed until **July 2024**). * **Independent Director:** **Mr. Srinivasa Rao Koyyalamudi** (Term: **2025–2030**), bringing expertise in **digital twins, digital transformation, and sustainability**. --- ### Risk Profile & Mitigation Framework Samsrita Labs operates in high-barrier, highly regulated sectors. The **Risk Management Committee** monitors the following: * **Operational Risks:** Long gestation periods in R&D, high upfront capital requirements for waste management, and the risk of **technological obsolescence**. * **Legal & Litigation Risks:** * Ongoing legal proceedings in the **NCLT** and **CCS, Hyderabad** involving **Krisani Bio Sciences** regarding allegations of criminal breach of trust and fraud. * The company faced an **Auditor Resignation** in September 2023 due to scaled-down operations and fee disputes. * **Market Risks:** Exposure to **fluctuating commodity prices** in the recycling sector and competition from traditional landfilling. * **Financial Risks:** * **Liquidity Risk:** Rated as **Minimal**; managed by ensuring funds meet immediate requirements. * **Interest Rate Risk:** **No significant exposure** as instruments are held at **Fixed Interest Rates**. * **Credit Risk:** Managed via an **Expected Credit Loss (ECL)** model. ### Investment Outlook Samsrita Labs is a **speculative growth play** transitioning from a stagnant healthcare service model to a diversified technology and life sciences incubator. While current revenues are minimal and legal complexities persist regarding its associate company, the aggressive acquisition of IP, the expansion into the **Pet Healthcare** and **Green Tech** sectors, and the recent capital infusion via preferential issues suggest a management pivot toward high-growth industrial trends.